What’s causing drug companies to go bust
As far as M&A deals go, 2019 has started off with a boom.
Lucrative compensation packages for CEOs are certainly not unique to pharma. But many of the industry's top dogs got hefty raises last year, showing it's a good time to be a CEO in pharma.
Leveraging data will not only help pharma predict asset failures, but also eliminate them